

BIOSIMILARS COMPETITION REDUCE COSTS



After Biosimilars Launch, Reference Biologics' List Price Increases Stop and Net Costs Fall

Reference Biologic	Biosimilars on Market	Initial List Price per Dosage Form	Current List Price per Dosage Form ¹	Total List Price % Change	Number of List Price Increases Since Launch	Most Recent List Price Increase	Date of First Biosimilar Launch	Net Cost ² % Change 2018–2020
Neupogen (filgrastim)	2	\$129.00 per vial	\$314.83 per vial	144%	29	10/19/2017	5/4/2018	1%
Epogen (epoetin-alfa)	1	\$20.00 per vial	\$33.16 per vial	66%	19	1/17/2017	5/22/2018	-34%
Neulasta (pegfilgrastim)	3	\$2,360.00 per syringe	\$6,231.06 per syringe	164%	28	1/1/2018	7/9/2018	-32%
Rituxan (rituximab)	2	\$31.80 per vial	\$93.95 per vial	195%	35	7/1/2018	11/9/2019	-14%
Avastin (bevacizumab)	2	\$137.5 per vial	\$199.23 per vial	45%	17	7/1/2018	7/18/2019	N/A ³
Herceptin (trastuzumab)	5	\$1,426.17 per vial	\$1,558.42 per vial	9%	3	7/1/2018	11/4/2019	-15%
Remicade (infliximab)	3	\$470.25 per vial	\$1,167.82 per vial	148%	22	2/9/2017	10/17/2016	-29%
Enbrel (etanercept)	0	\$110 per vial	\$746.02 per vial	578%	31	1/22/2021	N/A	6%
Humira (adalimumab)	0	\$522.5 per syringe	\$2,984.09 per syringe	471%	27	1/1/2021	N/A	8%

Currently, 7 reference biologics have at least 1 biosimilar competitor on the market, creating direct competition for those drugs.

- Since having a biosimilar come to market, only 1 of the 7 biologics had a list price increase. The list price for Remicade increased by 5% just four months after biosimilar launch but has not increased since.
- Prior to having a biosimilar on the market, the list prices for these 7 reference biologics with biosimilar competition increased an average of 21 times.
- Net cost for 5 of the 7 reference biologics with a biosimilar competitor on the market has decreased between 2018 to 2020.
- Enbrel and Humira are the only 2 biologics that have not had a biosimilar launch due to patent litigation in the US, without biosimilar competition list prices increased by 578.2% (Enbrel) and 471.12% (Humira) since launch.

Sources: PCMA research based on SSR Health analysis of Symphony Health Solutions; AnalySource® — Reprinted with permission by First Databank, Inc. All rights reserved © (2021).

Notes: List prices are wholesale acquisition cost (WAC), which represents the manufacturer's published catalog or list price for a drug product to wholesalers and may not represent actual transactional prices. For more information on methodology see First Databank <http://www.fdbhealth.com/policies/drug-pricing-policy/>. Sizing and dosing of vials and syringes differ across products.

1 Current list price as of June 2021.

2 Net cost is net sales reported by manufacturers divided by units, based on information reported by Symphony Health.

3 SSR Health has no net cost for Avastin in 2018–2020.